Crescent Biopharma (CBIO) Preferred Shares (2013 - 2026)

Crescent Biopharma (CBIO) reported Preferred Shares of $4.0 million for Q1 2026, little changed quarter-over-quarter from $4.0 million in Q4 2025.

Crescent Biopharma (CBIO) Preferred Shares (2013 - 2026) Analysis & Trends

Crescent Biopharma (CBIO) has 3 years of Preferred Shares data on file, last reported at $4.0 million in Q1 2026.

Preferred Shares for Q1 2026 came in at $4.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (changed N/A YoY), and the FY2025 annual result was $4.0 million, changed N/A from the prior year.
Preferred Shares was little changed at $4.0 million in Q1 2026 per CBIO's latest filing, from $4.0 million in the prior quarter.
Over five years, Preferred Shares peaked at $4.0 million in Q2 2025 and troughed at $4.0 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Shares (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Crescent Biopharma	486.92 Mn	297.76 Mn	-	4.00 Mn

Download Data